Berinert is the first C1-esterase inhibitor to be licensed for the treatment of hereditary angioedema, a condition characterised by a deficiency of C1-esterase.

Berinert is suitable for use in adults, children and neonates.

View Berinert drug record

Further information: CSL Behring

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in